Mini Review
Volume 13:11, 2022

Journal of
Nuclear Medicine & Radiation Therapy

ISSN: 2155-9619

Open Access

Rhenium Radioisotopes in Medicine: Manufacture and Uses

Licia Uccelli*

Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy

Abstract

The diagnosis and treatment of disease make use of radioisotopes of a wide variety of elements, the majority of which are metals, in nuclear medicine. A chelator that effectively forms thermodynamically and kinetically stable complexes with the metal ions' radioisotopes, or radiometals, is necessary for these applications. Additionally, the chelator attaches to a biological targeting vector to locate diseased tissues. While numerous chelators that are suitable for small radiometals have been developed, chelators that are effective for large radiometals are much less common. In this Report, we discuss recent developments in the development of ligands for the chelation of large radiometals, which have potential applications in nuclear medicine.

Keywords: Extraction chromatography • Photonuclear reactions • Radiochemical recovery

Introduction

Radioisotopes, also known as radioactive isotopes, are atoms that have unstable nuclei, meaning that they undergo decay and emit radiation in the form of alpha, beta, or gamma particles. These isotopes have important applications in medicine, including diagnosis, treatment and research. One of the most common uses of radioisotopes in medicine is for diagnostic imaging. In this technique, a small amount of a radioactive isotope is introduced into the patient's body, usually through injection or ingestion. The isotope then travels to the area of interest and emits radiation, which can be detected by a specialized camera or scanner. This creates an image of the internal structures of the body, allowing doctors to diagnose a variety of conditions. There are several different radioisotopes that are commonly used for diagnostic imaging. One of the most widely used is technetium-99m, which is a short-lived isotope that emits gamma radiation. Technetium-99m is used in a variety of imaging procedures, including bone scans, myocardial perfusion imaging and lung scans [1].

Literature Review

The use of alpha in recent decades; only beta; or beta/gamma emitters in rheumatology, endocrinology and interventional cardiology, has proven to be a useful alternative to the most common treatment protocols. Two rhenium radioisotopes are particularly relevant among the radionuclides utilized in nuclear medicine for treatment: the elements rhenium 186 and 188. The first is typically produced in nuclear reactors through the 185Re(n,)186Re nuclear reaction, which involves the direct activation of rhenium-186 by neutrons. The decay of the parent tungsten-188 results in the formation of rhenium-188. A chromatographic 188W/188Re generator, which is similar to the 99Mo/99mTc generator system in that tungsten-188 is adsorbed on the alumina column and the radionuclide is eluted in saline solution, is primarily used for the separation of rhenium-188. The specific activity of rhenium-186 and rhenium-188 determines their application. Rhenium-186 is a low-specific-activity element that is mostly used to label particles or make diphosphonates to treat bone pain. Rhenium-188, on the other hand, has a high specific activity and can be used to label bioactive molecules or peptides. Rhenium's chemical similarity to technetium is one of its benefits. As a result, radiorhenium-labeled diagnostic technetium analogs can be developed for therapeutic purposes. Particularly, 186/188Re-radiopharmaceutical-promoting clinical trials are discussed.

***Address for Correspondence:** Licia Uccelli, Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy; E-mail: U.licia44@gmail.com*

Received: 29 October, 2022, Manuscript No. jnmrt-23-90731; **Editor Assigned:** 31 October, 2022, PreQC No. P-90731; **Reviewed:** 15 November, 2022, QC No. Q-90731; **Revised:** 21 November, 2022, Manuscript No. R-90731; **Published:** 28 November, 2022, DOI: 10.37421/2155-9619.2022.13.515

Discussion

Finally, dual size selectivity chelators are discussed. Both large and small metal ions are well-suited to this group of ligands. Applications in nuclear medicine requiring the simultaneous chelation of both large and small radiometals with complementary therapeutic and diagnostic properties can benefit from this property. This selectivity pattern was recently described by the 18-membered macrocyclic ligand called macrodipa. In addition, this chelator, its second-generation analogue py-macrodipa and their applications for chelating the medicinally useful large 135La3+, 225Ac3+, 213Bi3+ and small 44Sc3+ ions are discussed. Studies with these radiometals demonstrate that py-macrodipa can reliably retain both small and large radiometals and effectively radiolabel them. In general, this Account argues in favor of novel arising radiometal ions with unusual coordination chemistry properties being utilized in novel ligand design strategies.

Ionizing radiation is used in the treatment and diagnosis of diseases in nuclear medicine, a significant branch of radiology. The use of internally administered radionuclides in the form of radiopharmaceutical agents is one area of this field that has received a lot of attention in the last two decades. In positron emission tomography (PET) and single-photon emission computed tomography (SPECT), radionuclides that undergo radioactive decay through positron emission, electron capture, or internal conversion are utilized for diagnostic purposes. In contrast, therapy is carried out with radionuclides that produce "particles," "particles," or Auger electrons. Nearly every element on the periodic table contains radioisotopes useful in nuclear medicine. Large radiometals at the bottom of the periodic table (the fifth period and below) have recently been recognized for their diagnostic and therapeutic potential. There have been a lot of efforts to use them for these purposes.

Another commonly used radioisotope is iodine-131, which is used to diagnose and treat thyroid conditions. In diagnostic imaging, iodine-131 is taken up by the thyroid gland and emits gamma radiation, allowing doctors to image the gland and detect any abnormalities. In treatment, iodine-131 is used to destroy overactive thyroid tissue, such as in cases of thyroid cancer or hyperthyroidism. Radioisotopes also have important applications in cancer treatment. In this technique, a radioactive isotope is introduced into the patient's body, where it travels to the site of the tumor and emits radiation, which damages or kills cancer cells. This technique is known as radiation therapy and is often used in conjunction with other treatments, such as chemotherapy and surgery.

There are several different types of radioisotopes that are used for cancer treatment. One of the most widely used is cobalt-60, which emits gamma radiation and is used to treat a variety of cancers, including those of the brain, lung and prostate. Other isotopes, such as iodine-131 and yttrium-90, are used to target specific types of cancer, such as thyroid cancer and liver cancer. Radioisotopes also have important applications in research. They are used to study the behavior of cells and tissues in the body, as well as to develop new drugs and therapies. For example, carbon-14 is used to study the metabolism of cells, while tritium is used to study the movement of molecules within cells. Despite their many benefits, radioisotopes also pose certain risks. Exposure to high levels of radiation can damage or kill cells in the body, leading to serious health problems, including cancer. To minimize these risks, strict safety protocols are in place to ensure that radioisotopes are handled and disposed of safely [2-5].

Conclusion

Radioisotopes have revolutionized medicine by providing a powerful tool for diagnosis, treatment and research. They have allowed doctors to image the internal structures of the body, target cancer cells with radiation and study the behavior of cells and tissues in the body. While they do pose certain risks, these risks can be minimized through strict safety protocols. As our understanding of radioisotopes continues to grow, we can expect even more innovative uses for these powerful tools in the future.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Knapp Jr, F.F. "Rhenium-188-A generator-derived radioisotope for cancer therapy." *Cancer Biother Radiopharm* 13 (1998): 337-349.

2. Mushtaq, A. "Concentration of 99mTcO4−/188ReO4− by a single, compact, anion exchange cartridge." *Nucl Med Commun* 25 (2004): 957-962.

3. Chakravarty, Rubel, Ashutosh Dash, M.R.A. Pillai and Meera Venkatesh, et al. "Post-elution concentration of 188Re by an electrochemical method." *Appl Radiat Isot* 68 (2010): 2302-2305.

4. Mallia, Madhava B., Viju Chirayil and Ashutosh Dash. "Improved freeze-dried kit for the preparation of 188ReN-DEDC/lipiodol for the therapy of unresectable hepatocellular carcinoma." *Appl Radiat Isot* 137 (2018): 147-153.

5. Bolzati, Cristina, Alessandra Boschi, Licia Uccelli and Rodolfo Franceschini, et al. "An alternative approach to the preparation of 188Re radiopharmaceuticals from generator-produced [188ReO4]−: efficient synthesis of 188Re (V)-meso-2, 3-dimercaptosuccinic acid." *Nucl Med Biol* 27 (2000): 309-314.

How to cite this article: Uccelli, Licia. “Rhenium Radioisotopes in Medicine: Manufacture and Uses.” J Nucl Med Radiat Ther 13 (2022): 515.